Efficacy of TNF α blockade in cyclophosphamide resistant neuro-Behçet disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 12, 2005, Pages 1733-1735

  Ribi, Camilo ^a   Sztajzel, R ^a   Delavelle, J ^a   Chizzolini, C ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; INFLIXIMAB; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; BEHCET DISEASE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; EYE DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MEDICAL EXAMINATION; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RELAPSE; SKIN MANIFESTATION; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 28144449548     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.055434     Document Type: Article

References (12)

1. Siva A, Kantarci OH, Saip S, et al. Behçet's disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 2001;248(2):95-103.
2. Kidd D, Steuer A, Denman AM, et al. Neurological complications in Behçet's syndrome. Brain 1999;122(Pt 11):2183-94.
3. Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease: soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997;24(1):128-32.
4. Evereklioglu C, Er H, Turkoz Y, et al. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002;11(2):87-93.
5. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993;20(9):1544-9.
6. Yamashita N, Kaneoka H, Kaneko S, et al. Role of gammadelta T lymphocytes in the development of Behçet's disease. Clin Exp Immunol 1997;107(2):241-7.
7. Freysdottir J, Lau S, Fortune F. Gammadelta T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999;118(3):451-7.
8. Ahmad T, Wallace GR, James T, et al. Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum 2003;48(3):807-13.
9. Sfikakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002;61(Suppl 2):ii51-3.
10. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44(9):1977-83.
11. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003;124(4):917-24.
12. Licata G, Pinto A, Tuttolomondo A, et al. Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome. Ann Rheum Dis 2003;62(3):280-1.